LSA
CPRX

Leonteq Securities AG’s Catalyst Pharmaceutical CPRX Stock Holding History

Leonteq Securities AG’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.1K Sell
1,912
-2,056
-52% -$60.7K ﹤0.01% 772
2026
Q1 		$98.2K Buy
3,968
+1,707
+75% +$40.7K ﹤0.01% 738
2025
Q4 		$52.8K Hold
2,261
– – ﹤0.01% 945
2025
Q3 		$44.5K Sell
2,261
-439
-16% -$9.03K ﹤0.01% 901
2025
Q2 		$58.6K Sell
2,700
-23
-0.8% -$543 ﹤0.01% 821
2025
Q1 		$65.8K Sell
2,723
-502
-16% -$11.3K ﹤0.01% 793
2024
Q4 		$69.2K Sell
3,225
-84
-3% -$1.8K ﹤0.01% 760
2024
Q3 		$65.8K Buy
3,309
+1,266
+62% +$23.5K 0.01% 706
2024
Q2 		$31.6K Buy
2,043
+98
+5% +$1.53K ﹤0.01% 849
2024
Q1 		$31K Buy
+1,945
New +$29.3K ﹤0.01% 858
2022
Q3 		– Sell
-4,000
Closed -$28K – 1294
2022
Q2 		$28K Buy
+4,000
New +$29.3K ﹤0.01% 934
2021
Q4 		– Sell
-4,000
Closed -$21.2K – 1272
2021
Q3 		$21.2K Hold
4,000
– – ﹤0.01% 982
2021
Q2 		$23K Buy
+4,000
New +$20.6K ﹤0.01% 931

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Leonteq Securities AG's CPRX Position: Q2 2026 in Review

Leonteq Securities AG reduced its Catalyst Pharmaceutical (CPRX) stake by 52% in Q2 2026, selling an estimated $60.7K and leaving 1,912 shares worth $60.1K. The position accounts for ﹤0.01% of the portfolio, ranked #772.

Leonteq Securities AG first reported a position in CPRX in Q2 2021 and has held it in 13 quarters since. The position peaked at $98.2K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Leonteq Securities AG held 1,912 shares of Catalyst Pharmaceutical worth $60.1K as of Q2 2026.
  • Leonteq Securities AG sold 2,056 Catalyst Pharmaceutical shares in Q2 2026, an estimated $60.7K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #772 holding.
  • Leonteq Securities AG first reported a position in Catalyst Pharmaceutical in Q2 2021 and has held it in 13 quarters since.
  • Leonteq Securities AG's Catalyst Pharmaceutical position peaked at $98.2K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.